<h3>在這個假期季節，TipRanks 限時 70% 折扣</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，最大化您的投資組合潛力</li>
</ul>
<p>Astria Therapeutics (ATXS) 的公告現已發佈。</p>
<p>2025 年 10 月 14 日，Astria Therapeutics 與 BioCryst Pharmaceuticals 及其子公司簽署了合併協議，子公司將合併入 Astria，使 Astria 成為 BioCryst 的全資子公司，BioCryst 已提交相關注冊聲明，而 Astria 則已發佈關於該交易的最終代理聲明以供股東投票。在 2025 年 12 月中旬，紐約州法院提起了兩起股東訴訟，指控 Astria 及其董事會在合併中疏忽地發佈了虛假和誤導性的註冊聲明，並尋求禁令救濟、損害賠償和費用，但公司已駁回這些索賠，認為其沒有依據，辯稱任何所謂的錯誤陳述都不重要或不可訴，並承諾將積極捍衞訴訟，同時繼續推進合併進程。</p>
<p>(ATXS) 股票的最新分析師評級為持有，目標價為 13.00 美元。要查看 Astria Therapeutics 股票的完整分析師預測列表，請訪問 ATXS 股票預測頁面。</p>
<p><strong>Spark 對 ATXS 股票的看法</strong></p>
<p>根據 Spark，TipRanks 的 AI 分析師，ATXS 的評級為中性。</p>
<p>Astria Therapeutics 的股票評分反映了其作為一家開發階段生物技術公司的地位。強勁的資產負債表提供了財務穩定性，但缺乏收入和不斷增加的虧損帶來了重大風險。混合的技術指標和估值挑戰進一步加劇了謹慎的前景。</p>
<p>要查看 Spark 對 ATXS 股票的完整報告，請點擊這裏。</p>
<p><strong>關於 Astria Therapeutics 的更多信息</strong></p>
<p>Astria Therapeutics, Inc. 是一家位於特拉華州的生物製藥公司，其股份由公眾股東持有，並由董事會監督，正受到 BioCryst Pharmaceuticals 的收購，完成計劃中的合併後將成為全資子公司。</p>
<p><strong>平均交易量：</strong> 2,078,799</p>
<p><strong>技術情緒信號：</strong> 持有</p>
<p><strong>當前市值：</strong> 732.4M 美元</p>
<p>要對 ATXS 股票進行全面評估，請訪問 TipRanks 的股票分析頁面。</p>

BioCryst制藥

<p>Astria Therapeutics 面臨股東針對其與 BioCryst Pharmaceuticals 計劃合併的訴訟。這些訴訟指控存在虛假和誤導性的註冊聲明，尋求禁令救濟和賠償。Astria 否認這些指控，承諾在推進合併的同時捍衞訴訟。分析師對 Astria 的股票評級為持有，目標價為 13.00 美元，指出其財務穩定，但因缺乏收入和不斷增加的虧損而對風險表示謹慎</p>

<h3>Claim 70% Off TipRanks This Holiday Season</h3>
<div class="lb-trans"><h3>在這個假期季節，TipRanks 限時 70% 折扣</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，最大化您的投資組合潛力</li>
</ul>
</div><p>An announcement from Astria Therapeutics ( (ATXS) ) is now available.</p>
<div class="lb-trans"><p>Astria Therapeutics (ATXS) 的公告現已發佈。</p>
</div><p>On October 14, 2025, Astria Therapeutics entered into a merger agreement with BioCryst Pharmaceuticals and a BioCryst subsidiary under which the subsidiary will merge into Astria, leaving Astria as a wholly owned unit of BioCryst, and BioCryst has filed the related registration statement while Astria has issued a definitive proxy statement for a stockholder vote on the deal. In mid-December 2025, two stockholder lawsuits were filed in New York state court alleging that Astria and its board negligently issued a false and misleading registration statement regarding the merger and seeking injunctive relief, damages, and fees, but the company has rejected the claims as without merit, arguing that any alleged misstatements are not material or actionable and pledging to vigorously defend the litigation while continuing to move the merger process forward.</p>
<div class="lb-trans"><p>2025 年 10 月 14 日，Astria Therapeutics 與 BioCryst Pharmaceuticals 及其子公司簽署了合併協議，子公司將合併入 Astria，使 Astria 成為 BioCryst 的全資子公司，BioCryst 已提交相關注冊聲明，而 Astria 則已發佈關於該交易的最終代理聲明以供股東投票。在 2025 年 12 月中旬，紐約州法院提起了兩起股東訴訟，指控 Astria 及其董事會在合併中疏忽地發佈了虛假和誤導性的註冊聲明，並尋求禁令救濟、損害賠償和費用，但公司已駁回這些索賠，認為其沒有依據，辯稱任何所謂的錯誤陳述都不重要或不可訴，並承諾將積極捍衞訴訟，同時繼續推進合併進程。</p>
</div><p>The most recent analyst rating on (ATXS) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Astria Therapeutics stock, see the ATXS Stock Forecast page.</p>
<div class="lb-trans"><p>(ATXS) 股票的最新分析師評級為持有，目標價為 13.00 美元。要查看 Astria Therapeutics 股票的完整分析師預測列表，請訪問 ATXS 股票預測頁面。</p>
</div><p><strong>Spark’s Take on ATXS Stock</strong></p>
<div class="lb-trans"><p><strong>Spark 對 ATXS 股票的看法</strong></p>
</div><p>According to Spark, TipRanks’ AI Analyst, ATXS is a Neutral.</p>
<div class="lb-trans"><p>根據 Spark，TipRanks 的 AI 分析師，ATXS 的評級為中性。</p>
</div><p>Astria Therapeutics’ stock score reflects its status as a development-stage biotech company. The strong balance sheet provides financial stability, but the lack of revenue and increasing losses pose significant risks. Mixed technical indicators and valuation challenges further contribute to a cautious outlook.</p>
<div class="lb-trans"><p>Astria Therapeutics 的股票評分反映了其作為一家開發階段生物技術公司的地位。強勁的資產負債表提供了財務穩定性，但缺乏收入和不斷增加的虧損帶來了重大風險。混合的技術指標和估值挑戰進一步加劇了謹慎的前景。</p>
</div><p>To see Spark’s full report on ATXS stock, click here.</p>
<div class="lb-trans"><p>要查看 Spark 對 ATXS 股票的完整報告，請點擊這裏。</p>
</div><p><strong>More about Astria Therapeutics</strong></p>
<div class="lb-trans"><p><strong>關於 Astria Therapeutics 的更多信息</strong></p>
</div><p>Astria Therapeutics, Inc. is a Delaware-based biopharmaceutical company, with its shares held by public stockholders and overseen by a board of directors, that is the target of an acquisition by BioCryst Pharmaceuticals, under which it would become a wholly owned subsidiary following completion of a planned merger.</p>
<div class="lb-trans"><p>Astria Therapeutics, Inc. 是一家位於特拉華州的生物製藥公司，其股份由公眾股東持有，並由董事會監督，正受到 BioCryst Pharmaceuticals 的收購，完成計劃中的合併後將成為全資子公司。</p>
</div><p><strong>Average Trading Volume:</strong> 2,078,799</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 2,078,799</p>
</div><p><strong>Technical Sentiment Signal:</strong> Hold</p>
<div class="lb-trans"><p><strong>技術情緒信號：</strong> 持有</p>
</div><p><strong>Current Market Cap:</strong> $732.4M</p>
<div class="lb-trans"><p><strong>當前市值：</strong> 732.4M 美元</p>
</div><p>For a thorough assessment of ATXS stock, go to TipRanks’ Stock Analysis page.</p>
<div class="lb-trans"><p>要對 ATXS 股票進行全面評估，請訪問 TipRanks 的股票分析頁面。</p>
</div>

Astria 因計劃與 BioCryst 製藥合併而面臨股東訴訟